Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate

For decades, Professor Claude Wischik, co-founder and CEO of TauRx, has led a scientific research team dedicated to finding an effective treatment for neurodegenerative diseases.

TauRx recently completed its latest Phase III clinical trials in Alzheimer’s disease and in the rare neurodegenerative disorder, behavioural variant frontotemporal dementia (bvFTD).

Maintaining integrity, accountability and transparency in our pursuit of life-changing treatments